BSBhaskar Saha

Bhaskar Saha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bhaskar Saha has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Host-Kinetoplastid Parasite Interaction at the Immune System Interface: Immune Evasion and Immunotherapy

    by Arathi Nair, Sunil Kumar, Bhaskar Saha, Divanshu Shukla

    Written by authors active in the field of Leishmania and Trypanosoma research, this volume reviews the current research in kinetoplastid parasites with an emphasis on cellular and molecular biology. Includes epigenetic regulation, cellular defence, manipulation of host macrophages, B lymphocyte response, adhesion and invasion of host tissues, immune evasion, immunotherapy, hemeproteins, phospholipids biosynthesis and DNA topoisomerases.

  • Open Access

    Spatio-Temporal Regulation of PKC Isoforms Imparts Signaling Specificity

    by Arkajyoti Mukherjee, Sayoni Roy, Bhaskar Saha, Debasri Mukherjee

    Spatio-Temporal Regulation of PKC Isoforms Imparts Signaling Specificity


  • Platelet-Activating Factor Receptor Contributes to Antileishmanial Function of Miltefosine

    by Pallavi R. Gangalum, Waldionê de Castro, Leda Q. Vieira, Ranadhir Dey, Luis Rivas, Shailza Singh, Subrata Majumdar, Bhaskar Saha

    Miltefosine [hexadecylphosphocholine (HPC)] is the only orally bioavailable drug for the disease visceral leishmaniasis, which is caused by the protozoan parasite Leishmania donovani. Although miltefosine has direct leishmanicidal effects, evidence is mounting for its immune system–dependent effects. The mechanism of such indirect antileishmanial effects of miltefosine remains to be discovered. As platelet-activating factor and HPC share structural semblances and both induce killing of intracellular Leishmania, we surmised that platelet-activating factor (PAF) receptor had a significant role in the antileishmanial function of miltefosine. The proposition was supported by molecular dynamic simulation of HPC docking into PAF receptor and by comparison of its leishmanicidal function on PAF receptor–deficient macrophages and mice under HPC treatment. We observed that compared with wild-type macrophages, the PAF receptor–deficient macrophages showed 1) reduced binding of a fluorescent analog of HPC, 2) decreased TNF-α production, and 3) lower miltefosine-induced killing of L. donovani. Miltefosine exhibited significantly compromised leishmanicidal function in PAF receptor–deficient mice. An anti-PAF receptor Ab led to a significant decrease in miltefosine-induced intracellular Leishmania killing and IFN-γ production in a macrophage–T cell coculture system. These results indicate significant roles for PAF receptor in the leishmanicidal activity of HPC. The findings open new avenues for a more rational understanding of the mechanism of action of this drug as well as for improved therapeutic strategies.


  • Inhibition of CD40-Induced N-Ras Activation Reduces Leishmania major Infection

    by Sushmita Chakraborty, Ankita Srivastava, Mukesh Kumar Jha, Arathi Nair, Surya Prakash Pandey, Neetu Srivastava, Sangeeta Kumari, Shailza Singh, Musti V. Krishnasastry, Bhaskar Saha

    Leishmania major is a parasite that resides and replicates in macrophages. We previously showed that the parasite enhanced CD40-induced Raf-MEK-ERK signaling but inhibited PI3K-MKK-p38MAPK signaling to proleishmanial effects. As Raf and PI3K have a Ras-binding domain but exert opposite effects on Leishmania infection, we examined whether Ras isoforms had differential roles in Leishmania infection. We observed that L. major enhanced N-Ras and H-Ras expression but inhibited K-Ras expression in macrophages. L. major infection enhanced N-Ras activity but inhibited H-Ras and K-Ras activity. TLR2 short hairpin RNA or anti-TLR2 or anti-lipophosphoglycan Abs reversed the L. major–altered N-Ras and K-Ras expressions. Pam3CSK4, a TLR2 ligand, enhanced N-Ras expression but reduced K-Ras expression, indicating TLR2-regulated Ras expression in L. major infection. Whereas N-Ras silencing reduced L. major infection, K-Ras and H-Ras silencing enhanced the infection both in macrophages in vitro and in C57BL/6 mice. BALB/c-derived macrophages transduced with lentivirally expressed N-Ras short hairpin RNA and pulsed with L. major–expressed MAPK10 enhanced MAPK10-specific Th1-type response. CD40-deficient mice primed with these macrophages had reduced L. major infection, accompanied by higher IFN-γ but less IL-4 production. As N-Ras is activated by Sos, a guanine nucleotide exchange factor, we modeled the N-Ras–Sos interaction and designed two peptides from their interface. Both the cell-permeable peptides reduced L. major infection in BALB/c mice but not in CD40-deficient mice. These data reveal the L. major–enhanced CD40-induced N-Ras activation as a novel immune evasion strategy and the potential for Ras isoform–targeted antileishmanial immunotherapy and immunoprophylaxis.


  • Pegylated Bisacycloxypropylcysteine, a Diacylated Lipopeptide Ligand of TLR6, Plays a Host-Protective Role against Experimental Leishmania major Infection

    by Surya Prakash Pandey, Himanshu Singh Chandel, Sunit Srivastava, Sathishkumar Selvaraj, Mukesh Kumar Jha, Divanshu Shukla, Thomas Ebensen, Carlos A Guzman, Bhaskar Saha

    TLRs recognize pathogen-expressed Ags and elicit host-protective immune response. Although TLR2 forms heterodimers with TLR1 or TLR6, recognizing different ligands, differences in the functions of these heterodimers remain unknown. In this study, we report that in Leishmania major-infected macrophages, the expression of TLR1 and TLR2, but not TLR6, increased; TLR2–TLR2 association increased, but TLR2–TLR6 association diminished. Lentivirus-expressed TLR1–short hairpin RNA (shRNA) or TLR2–shRNA administration reduced, but TLR6–shRNA increased L. major infection in BALB/c mice. Corroboratively, Pam3CSK4 (TLR1–TLR2 ligand) and peptidoglycan (TLR2 ligand) increased L. major infection but reduced TLR9 expression, whereas pegylated bisacycloxypropylcysteine (BPPcysMPEG; TLR2–TLR6 ligand) reduced L. major number in L. major-infected macrophages, accompanied by increased TLR9 expression, higher IL-12 production, and inducible NO synthase expression. Whereas MyD88, Toll/IL-1R adaptor protein, and TNFR-α–associated factor 6 recruitments to TLR2 were not different in Pam3CSK4-, peptidoglycan-, or BPPcysMPEG-treated macrophages, only BPPcysMPEG enhanced p38MAPK and activating transcription factor 2 activation. BPPcysMPEG conferred antileishmanial functions to L. major-infected BALB/c-derived T cells in a macrophage–T cell coculture and in BALB/c mice; the protection was TLR6 dependent and IL-12 dependent, and it was accompanied by reduced regulatory T cell number. BPPcysMPEG administration during the priming with fixed L. major protected BALB/c mice against challenge L. major infection; the protection was accompanied by low IL-4 and IL-10, but high IFN-γ productions and reduced regulatory T cells. Thus, BPPcysMPEG, a novel diacylated lipopeptide ligand for TLR2–TLR6 heterodimer, induces IL-12–dependent, inducible NO synthase–dependent, T-reg–sensitive antileishmanial protection. The data reveal a novel dimerization partner-dependent duality in TLR2 function.


  • Open Access

    SHP-1 Plays a Crucial Role in CD40 Signaling Reciprocity

    by Tabish Hasan Khan, Neetu Srivastava, Ankita Srivastava, Archana Sareen, Ram K. Mathur, Ajit G. Chande, Krishnasastry V. Musti, Somenath Roy, Robin Mukhopadhyaya, Bhaskar Saha

    CD40 plays dual immunoregulatory roles in Leishmania major infection and tumor regression. The functional duality emerges from CD40-induced reciprocal p38MAPK and ERK-1/2 phosphorylations. Because phosphotyrosine-based signaling in hematopoietic cells is regulated by the phosphotyrosine phosphatase SHP-1, which is not implied in CD40 signaling, we examined whether SHP-1 played any roles in CD40-induced reciprocal signaling and anti-leishmanial function. We observed that a weaker CD40 stimulation increased SHP-1 activation. ERK-1/2 inhibition or p38MAPK overexpression inhibited CD40-induced SHP-1 activation. An ultra-low-dose, CD40-induced p38MAPK phosphorylation was enhanced by SHP-1 inhibition but reduced by SHP-1 overexpression. A reverse profile was observed with ERK-1/2 phosphorylation. SHP-1 inhibition reduced syk phosphorylation but increased lyn phosphorylation; syk inhibition reduced but lyn inhibition enhanced CD40-induced SHP-1 phosphorylation. Corroborating these findings, in L. major–infected macrophages, CD40-induced SHP-1 phosphorylation increased and SHP-1 inhibition enhanced CD40-induced p38MAPK activation and inducible NO synthase expression. IL-10 enhanced SHP-1 phosphorylation and CD40-induced ERK-1/2 phosphorylation but reduced the CD40-induced p38MAPK phosphorylation, whereas anti–IL-10 Ab exhibited reverse effects on these CD40-induced functions, identifying IL-10 as a crucial element in the SHP-1-MAPK feedback system. Lentivirally overexpressed SHP-1 rendered resistant C57BL/6 mice susceptible to the infection. Lentivirally expressed SHP-1 short hairpin RNA enhanced the CD40-induced L. major parasite killing in susceptible BALB/c mice. Thus, we establish an SHP-1–centered feedback system wherein SHP-1 modulates CD40-induced p38MAPK activation threshold and reciprocal ERK-1/2 activation, establishing itself as a critical regulator of CD40 signaling reciprocity and mechanistically re-emphasizing its role as a potential target against the diseases where CD40 is involved.


  • Open Access

    TLR–CD40 Cross-Talk in Anti-Leishmanial Immune Response

    by Himanshu Singh Chandel, Surya Prakash Pandey, Sayoni Roy, Noelle Doyen, Bhaskar Saha

    Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns (PAMPs) and activate innate immune cells to induce cytokines and co-stimulatory molecules such as CD40 and to enhance antigen presentation to T cells (1) that, upon activation, can either eliminate or support the pathogen (2). Herein, we propose that this duality in TLR functions results from their cross-talk with CD40. While all TLRs enhance CD40 expression, CD40 augments the expression of only TLR9 (3). As both CD40 and TLR9 induce expression of IL-12, a cytokine that induces the IFN-γ secreting Th1 cell differentiation (4), the CD40–TLR9 cross-regulation implies a positive feedback loop. By contrast, TLR1–TLR2 heterodimer down-regulates TLR9 expression (5) and antagonizes the development of Th1 response but favors the differentiation of regulatory T (T-reg) cells (Pandey et al., unpublished observation). Low CD40 expression levels in dendritic cells also promote T-reg cell differentiation (6). This duality can emerge from the sharing of signaling molecules. CD40 induces TRAF6-mediated, ERK-1/2-dependent IL-10 (7), which can inhibit the TLR-induced p38-MAPK activation and IL-12 production, antagonizing Th1 development. CD40-induced TRAF3-dependent p38-MAPK activation (7) can synergize with the TLR-activated p38-MAPK-dependent IL-12 production and Th1 differentiation. Using Leishmania infection, we show that the TLR–CD40 cross-talk can induce contrasting anti-leishmanial immune responses. Leishmania, a protozoan parasite, lives in macrophages. Leishmania expresses lipophosphoglycan (LPG), proteoglycans, flagellin, and profilin for possible recognition by the host cell-expressed TLRs. Recognition of the Leishmania-expressed PAMPs results in differential immune responses, which can either reduce or exacerbate Leishmania infection. As TLRs modulate the expression of CD40, a co-stimulatory molecule whose expression levels modulate anti-leishmanial T cell responses, we propose that TLR–CD40 cross-talk significantly regulate the outcome of an anti-leishmanial immune response. A pathogen is perceived as a “danger” when specific molecular patterns associated with it [PAMPs or damage-associated molecular patterns (DAMPs)] are recognized by a set of TLRs, the mammalian homologs of toll, the anti-fungal resistance-mediating receptor in Drosophila (8, 9). Of the 13 TLRs, TLR10 is not expressed in mice whereas TLR11, TLR12, and TLR13 are absent from human (10). The extracellular domain of TLRs contains leucine-rich repeats (LRRs) arranged in an alpha-helix and a beta-pleated sheet. The LRR-rich loops impart the flexibility to this domain required for accommodating wide variety of chemically different PAMPs (11). The intracellular C-terminal domain has a toll/interleukin-1 receptor motif responsible for TLR signaling (12). Some TLRs – TLR1, TLR2, TLR4, TLR5, TLR6, TLR10, TLR11, TLR12 g – are located on cell surface to recognize the PAMPs on pathogen surface. Other TLRs – TLR3, TLR7, TLR8, TLR9, TLR13 – are located intracellularly on endosomes, lysosomes, and endoplasmic reticulum (13) to recognize the nucleic acids from the degraded pathogen (14). Thus, PAMPs on pathogen surface are first recognized by the TLRs on host cell surface. Once the pathogen is internalized and degraded, the released nucleic acids are recognized by the intracellular TLRs. Recognition of the PAMPs by the TLRs on host cell surface triggers intracellular signaling that may result in one of the two contrasting outcomes (Figure 1, top panel). The Leishmania major parasites that express low levels of LPG are unable to reduce TLR9 expression and are eliminated by the macrophages (5). By contrast, the virulent parasites express higher levels of LPG, reduce TLR9 expression, and survive in macrophages (5). The lipoprotein analogs with modified acylations are preferentially recognized by TLR1 (15). Thus, pathogens may modify PAMPs that differentially bind to the TLRs on host cell surface and signal to modulate the expression and function of intracellular TLRs. Differential signaling may result in either elimination or growth of the intracellular pathogen. Isolation of different strains expressing modified PAMPs and assessments of immune response to those modified PAMPs are required to verify this hypothesis. Figure 1. TLR–CD40 cross-talk may result in one of two alternative possibilities. As the pathogen enters its host, it is recognized by cell surface TLRs. Depending on the PAMP–TLR interaction, the TLR may trigger signals with one of two possible fates of the pathogen. (A) In case of anti-inflammatory responses, the pathogen degradation inside the cell is impaired leading to less release of the pathogen nucleic acids. As a result, the intracellular TLRs are not optimally activated. The immune response against the pathogen is suppressed causing establishment of the infection. In case of Leishmania infection, CD40 signaling through p38-MAPK is suppressed. (B) Alternatively, where the signaling results in pro-inflammatory response, the intracellular pathogen is degraded and the intracellular TLRs are optimally activated. In L. major infection, the host-protective function of CD40 involves strong p38-MAPK activation with resultant IL-12-dependent Th1 response. The thicker arrows in (A,B) represent the dominant signaling. (C) Possible feedback loops are proposed. TLRs increase CD40 expression but CD40 enhances the expression of only TLR9, an intracellular TLR that recognizes CpG motifs in pathogen DNA. This can be viewed as a positive feedback loop for enhancing IL-12 production and Th1 response. The other arm of the loop is the TLR-activated MHC-II expression, which is linked to CD40 expression and DC maturation. This is also required for a stronger and prolonged immune response against a pathogen. CD40 is expressed on macrophages, dendritic cells, inflamed tissue histiocytes, and endothelial cells (16). CD40 signals though NF-κB to regulate the production of IL-12 (17), a pro-inflammatory cytokine required for Th1 differentiation (4). IL-4 is the cytokine that is required for the differentiation of Th2 cells, which produce IL-4, IL-5, and IL-13 (18). As a function of the strength of its stimulation, CD40 induces ERK-1/2-dependent IL-10 production (7). IL-10 expressed under MHC class-II promoter but not under IL-2 promoter aggravated Leishmania infection suggesting that the macrophage or the dendritic cell expressed IL-10 inhibited Th1 response (19). In L. major infection, the fate of the parasite is determined not only by Th1/Th2 balance but also by T-reg cells (6, 20–22) that produce IL-10, inhibiting Th1 differentiation but promoting infection (20–22). While low levels of CD40 expression on dendritic cells are required for T-reg cell expression (6), blockade of CD40–CD40L interaction on myeloid-derived suppressor cells (MDSCs) suppresses expansion of T-reg cells (23) suggesting CD40-induced dual regulation of T-reg cells. It is shown that in response to higher doses of its ligand, CD40 signals from the cholesterol-rich domain through lyn, PKC-β, and p38-MAPK to induce IL-12 production whereas in response to lower doses of the ligand, the same receptor signals from the cholesterol-poor domain through syk, PKC-ζ, and ERK-1/2 to induce IL-10 production; ERK-1/2 inhibition results in enhanced activation of p38-MAPK and vice versa (7, 24–26). CD40 signals reciprocally through a bimodularly arranged cascade of kinases, wherein the reciprocity is incorporated by two feedback loops between p38-MAPK and syk and between ERK-1/2 and lyn (26). Thus, although the mechanism of the duality in CD40 functions is established, how CD40 regulates the contrasting fates of T-reg cells remains to be elucidated. Toll-like receptors bind to their respective ligands and dimerize before recruiting the adaptor molecules – MyD88, TIRAP/MAL, TRIF, and TRAM. MyD88 and TIRAP/MAL belong to the MyD88-dependent pathway and signal through NF-κB. TRIF and TRAM constitute the MyD88-independent pathway. Only TLR3 signals through MyD88-independent pathway and only TLR4 signals through both pathways (27). TRAF6 is another adaptor that mediates the TLR signals (27). The signals finally converge on MAPKs and activate different transcription factors that effectuate the gene expressions (27). TLRs are differentially involved in T cell activation and T-reg cell development. For example, the T cell-expressed TLR4 promotes the suppressive function of T-reg cells whereas TLR6 abrogates its suppressive function (28). Thus, TLR4 and TLR6 act antagonistically to each other in regulating T-reg cell functions. By contrast, TLR2 alone plays contradictory roles in T-reg cell expansion and in its suppressive function (29–31). Among the TLRs, TLR2 represents a unique receptor, as it heterodimerizes with TLR1 or TLR6 or with TLR10, in human (32). The heterodimers broaden the repertoire of PAMPs recognized and may elicit different effector functions, which can even be counteractive. Some TLR2 ligands – arabinosylated lipoarabinomannan and lipoteichoic acid – induce pro-inflammatory responses (33, 34) but LPG, another TLR2 ligand, induces anti-inflammatory responses (5, 35, 36). The difference may result from the nature of the heterodimers recognizing the PAMPs. The TLR1/TLR2 heterodimer induces pro-inflammatory response whereas the TLR2/TLR6 heterodimer induces anti-inflammatory response or vice versa [(37); Pandey et al., unpublished results]. Besides forming heterodimers, TLR2 may form homodimer too. For example, SitC, a triacylated lipoprotein from Staphylococcus aureus, can induce cytokine response in the TLR1/TLR6-deficient macrophages (38). Although TLR2–TLR10 hetero-dimerization is a theoretical possibility, it appears unlikely because neither mice nor macrophages express TLR10. Although TLR1 and TLR6 cannot possibly recognize ligands or trigger signals on their own, their relative levels of expressions in a cell can determine the constitution of the predominant TLR2 heterodimer. The increased TLR2 expression in L. major-infected macrophages promotes TLR2 homo-dimerization, which is accentuated due to reduced TLR2–TLR6 association (Pandey et al., unpublished observation). In this case, because TLR2 homodimers are predominant and recruit primarily MyD88, TLR1–TLR2 and TLR2–TLR6 heterodimers may not be able to recruit enough MyD88. As the MAPKs and the transcription factors mediate TLR signaling (3, 39–41), the specificity, amplitude, and nature of the response will thus depend on the relative usage of these signaling intermediates. Thus, the plasticity in the TLR2-mediated recognition of PAMPs and elicitation of immune responses depend on the variations in the chemical structures of PAMPs, nature of TLR–PAMP interaction, recruitment of adaptor molecules, and competition between the TLRs for the available adaptor molecules. The response to an infection starts with the recognition of the PAMPs, perhaps, by multiple TLRs in tandem. Given the wide variety of PAMPs they recognize, the most probable TLRs to operate in tandem are TLR1, TLR2, TLR6, TLR10, and TLR4. In case of flagellated pathogens, TLR5 may recognize flagellin. The advantage of simultaneous trigger from TLR2 and TLR3 or TLR4 is that both MyD88-dependent and MyD88-independent pathways are involved increasing the overall strength and repertoire of TLR-derived signals. The combinations of TLRs may thus decide the nature of the signal and final effector functions (42) such as CD40 expressions that link the innate immune response to the adaptive immune response. In peritoneal macrophages, CD40 expression in response to poly-I:C, LPS, and CpG, the TLR3, TLR4, and TLR9 ligands, respectively, is substantially enhanced, whereas CD40 stimulation enhances the expression of only TLR9 (3). L. major DNA induces IL-12 through TLR9 (43). CpG and CD40-ligand induced more IL-12 production from macrophages (3) and splenic dendritic cells (44) than that induced by either agent alone. On the other hand, low strength CD40 signal may synergize with the signal from TLR1–TLR2 heterodimers to strongly induce IL-10, which can inhibit p38-MAPK activation (Figure 1A). The CD40-induced IL-10 self-limits the CD40-induced p38-MAPK activation and anti-leishmanial functions (24). A possible feedback that comes into play in this CD40–TLR synergy is the quenching of TRAF6 availability to CD40 to result in less CD40-induced IL-10 production and relieving the autocrine IL-10 mediated inhibition of CD40-induced p38-MAPK activation and IL-12 production. Alternatively, exhaustion of TRAF6 by simultaneous signaling by multiple TLRs may divert a strong CD40 signaling primarily through TRAF3 to result in p38-MAPK activation and IL-12 production (Figure 1B). Thus, the enhanced IL-12 production as a result of TLR9 and CD40 synergy may represent a positive feedback loop between TLR9 and CD40 (Figure 1C). These reports imply that the TLR–CD40 cross-talk modulates the ensuing adaptive immune response. Several reports support that TLRs can modulate CD40-mediated activation of adaptive immune system. PAMPs induce DC maturation by up-regulating MHC-II, CD40, and CD80/CD86 expressions (45) that are required for robust T cell responses. Because the binding of intracellular MHC-II with Btk via CD40 is required for sustained TLR activation, MHC-II deficiency impaired the TLR-induced production of pro-inflammatory cytokines and type-I interferon in macrophages and DC (46). CpG supported the survival and maturation of human plasmacytoid DC and, in synergy with CD40, induced T cells polarization to Th1 cells (47). Combined stimulation through TLR7 and CD40-induced CD8+ T cells expansion more than that observed with either agent alone (48). These reports indicate that CD40 and TLRs synergize to affect DC maturation, activation, survival, antigen presentation, and differentiation of CD4+ and CD8+ T cells. The TLR–CD40 cross-talk exemplifies that one of the fundamental physiological principles of maintaining homeostasis is the plasticity in receiving and processing signals. The signals from TLRs and CD40 modulate each other’s expression. Both receptors possess signaling plasticity modulating a range of effector functions (Figure 1) that affect both innate and adaptive immune systems. As pathogens sequentially involve cell surface and intracellular TLRs, the collective TLR activation or inhibition determines the CD40 expression levels. These evidences prompt a new model for the evolution of immune response. According to this model, TLR activation influences CD40 expression and signaling, resulting in both TLR and CD40 simultaneously signaling in the later phase of PAMP-induced innate immune response. As CD40 enhances TLR9 expression, TLR9, perhaps, through induction of IL-12 or further increase in CD40 expression, may further modulate the T cell response. Thus, a continued feedback between the TLR and CD40 during an immune response may finally decide the outcome of an infection. However, further verification of this model awaits detailed investigation. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The Department of Biotechnology (BT/PR/3288/BRB/10/966/2011) and CEFIPRA (F3303-4) provided financial assistance to this work. 1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5:987–95. doi: 10.1038/ni1112 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 2. Masopust D, Picker LJ. Hidden memories: frontline memory T cells and early pathogen interception. J Immunol (2012) 188:5811–7. doi:10.4049/jimmunol.1102695 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 3. Chandel HS, Pandey SP, Shukla D, Lalsare K, Selvaraj SK, Jha MK, et al. TLRs and CD40 modulate each others expression affecting Leishmania major infection. Clin Exp Immunol (2014) 176:283–90. doi:10.1111/cei.12264 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 4. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. Natural killer cell stimulatory factor induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med (1993) 177:1199–204. doi:10.1084/jem.177.4.1199 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 5. Srivastava S, Pandey SP, Jha MK, Chandel HS, Saha B. Leishmania expressed lipophosphoglycan interacts with toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses. Clin Exp Immunol (2013) 172:403–9. doi:10.1111/cei.12074 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 6. Martin S, Agarwal R, Murugaiyan G, Saha B. CD40 expression levels modulate regulatory T cells in Leishmania donovani infection. J Immunol (2010) 185:551–9. doi:10.4049/jimmunol.0902206 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 7. Rub A, Dey R, Jadhav M, Kamat R, Chakkaramakkil S, Majumdar S, et al. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat Immunol (2009) 10:273–80. doi:10.1038/ni.1705 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 8. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol (2011) 11:807–22. doi:10.1038/nri3095 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 9. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86:973–83. doi:10.1016/S0092-8674(00)80172-5 CrossRef Full Text 10. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637–50. doi:10.1016/j.immuni.2011.05.006 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 11. Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity (2008) 29:182–91. doi:10.1016/j.immuni.2008.07.007 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 12. Bowie A, O’Neill LA. The interleukin-1 receptor/toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol (2000) 67:508–14. Pubmed Abstract | Pubmed Full Text 13. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity (2010) 32:305–15. doi:10.1016/j.immuni.2010.03.012 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 14. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11:373–84. doi:10.1038/ni.1863 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 15. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol (2002) 169:10–4. doi:10.4049/jimmunol.169.1.10 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 16. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol (1997) 9:330–7. doi:10.1016/S0952-7915(97)80078-7 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text...


  • Open Access

    Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection

    by H S Chandel, S P Pandey, D Shukla, K Lalsare, S K Selvaraj, M K Jha, B Saha

    Summary: Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns and results in innate immune system activation that results in elicitation of the adaptive immune response. One crucial modulator of the adaptive immune response is CD40. However, whether these molecules influence each other's expression and functions is not known. Therefore, we examined the effects of TLRs on CD40 expression on macrophages, the host cell for the protozoan parasite Leishmania major. While polyinosinic-polycytidylic acid [poly (I:C)], a TLR-3 ligand, lipopolysaccharide (LPS), a TLR-4 ligand, imiquimod, a TLR-7/8 ligand and cytosine–phosphate–guanosine (CpG), a TLR-9 ligand, were shown to enhance CD40 expression, CD40 stimulation enhanced only TLR-9 expression. Therefore, we tested the synergism between CD40 and CpG in anti-leishmanial immune response. In Leishmania-infected macrophages, CpG was found to reduce CD40-induced extracellular stress-regulated kinase (ERK)1/2 activation; with the exception of interleukin (IL)-10, these ligands had differential effects on CD40-induced IL-1α, IL-6 and IL-12 production. CpG significantly enhanced the anti-leishmanial function of CD40 with differential effects on IL-4, IL-10 and interferon (IFN)-γ production in susceptible BALB/c mice. Thus, we report the first systematic study on CD40–TLR cross-talk that regulated the experimental L. major infection.


  • Open Access

    Anti-VEGF antibody enhances the antitumor effect of CD40

    by Sathishkumar Selvaraj, Mahesh Raundhal, Ashok Patidar, Bhaskar Saha

    As its central immunomodulatory effects, CD40 induces interleukin (IL)-12-dependent antitumor immune responses; as its local protumor effects, CD40 induces the expression of vascular endothelial growth factor (VEGF) that promotes tumor angiogenesis and growth. Therefore, using a previously established tumor model in mouse, we examined if the antitumor functions of CD40 are self-limited by VEGF induction. We observed that as the tumor mass grew during day 6 to day 18, VEGF expression in the tumor peaked with concomitant decrease in expressions of CD40 and IL-12 but not of IL-10. Among the angiogenic factors, VEGF-B, VEGFR-1, VEGFR-2, angiopoietin-1 and Tie2 expressions decreased, whereas the expressions of angiopoietin-2 and angiopoietin-3 increased with tumor growth. As significant changes in the expressions of these factors were observed on day 6, we treated the tumor-bearing mice with the agonistic anti-CD40 antibody or neutralizing anti-VEGF antibody—alone or in combination—from the fifth day after the injection of tumor cells. The anti-VEGF antibody significantly enhanced the antitumor effects of the anti-CD40 antibody, as observed through increased survival of the mice, accompanied by reduced angiogenesis and angiopoietin-2 expression but higher T-cell proliferation in response to tumor antigens, increased interferon-γ production and tumor cell cytotoxicity and higher levels of tumor antigen-specific serum IgM, IgG1 and IgG2a, indicating B-cell activation. Thus, our data show for the first time that the combined treatment with an agonistic anti-CD40 antibody and a neutralizing anti-VEGF antibody, which increases antitumor immune response or reduces local angiogenesis, respectively, is a novel antitumor strategy.